title: Glucocorticoid-mediated enhancement of glutamatergic transmission may outweigh anti-inflammatory effects under conditions of neuropathic pain.
abstract: At the clinical level comorbidity between chronic pain and dysfunctional hypothalamus-pituitary-adrenal (HPA) axis is well established. We aimed to identify causal relationships in a model of neuropathic pain (chronic constriction injury, CCI) by studying the effects of glucocorticoid receptor agonist (dexamethasone) and antagonist (RU-486) administration on pain behavior and spinal biochemical mediators. Daily injections were performed in Sprague Dawley rats. Weight, plasma corticosterone levels and mechanical pain thresholds were assessed before and during 21 days post-CCI. At days four and 21 we investigated the mRNA expression of spinal mediators. In the dexamethasone-injected group, we observed a diminution of body weight and plasma corticosterone levels during the 21 days post surgery period and a more pronounced pain sensitivity until day 7 post-CCI. This enhanced pain sensitivity in the early period following nerve injury was accompanied by a transient increase of the glutamate receptors mGluR5 and NMDA at day 4. However, at this time point we did not observe any effect of the agonist/antagonist injections on the mRNA expression of pro-inflammatory cytokines. The RU-486-injected rats showed a slight mechanical hypoalgesia until 7 days post-CCI, but without any significant correlation with the expression of the measured markers. Our results indicate that glucocorticoid-related modulations of neuropathic pain processing may rather depend on a modification of glutamatergic transmission than on a change in pro-inflammatory cytokine expression.
authors.affiliation: Laboratory of Neurophysiology & Psychobiology, University of Luxembourg, Luxembourg, Luxembourg.
authors.forename: Glenn-Marie
authors.initials: GM
authors.lastname: Le Coz
authors.affiliation: Laboratory of Neurophysiology & Psychobiology, University of Luxembourg, Luxembourg, Luxembourg.
authors.forename: Fernand
authors.initials: F
authors.lastname: Anton
authors.affiliation: Laboratory of Neurophysiology & Psychobiology, University of Luxembourg, Luxembourg, Luxembourg.
authors.forename: Ulrike
authors.initials: U
authors.lastname: Hanesch
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D015870:Gene Expression; D005938:Glucocorticoids / Q000378:metabolism* / Q000494:pharmacology; D018698:Glutamic Acid / Q000378:metabolism*; D008297:Male; D015735:Mifepristone / Q000008:administration & dosage / Q000494:pharmacology; D009437:Neuralgia / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D017288:Pain Threshold / Q000187:drug effects; D059348:Peripheral Nerve Injuries / Q000150:complications; D051381:Rats; D011965:Receptors, Glucocorticoid / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D005938:Glucocorticoids; D011965:Receptors, Glucocorticoid; D015735:Mifepristone; D018698:Glutamic Acid